Publication | Closed Access

The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence

OncologyCyclooxygenase-2-selective InhibitorsOncogenic AgentMedicineGastroenterologyPathologyColorectal CancerAnti-cancer AgentPharmacologyCancer Research